LXRX as reported
Lexicon Pharmaceuticals, Inc. reported $70M of revenue over the trailing twelve months, +123% on the year before. 10 reported series are charted on this page, each one as filed.
$70M
Revenue, trailing twelve months · to Q1 2026 · +123% against the twelve months before
- Net Income
- −$26M
Net Income · −85% year on year · trailing twelve months to Q1 2026
- Op Margin
- −87%
Op Margin · trailing twelve months to Q1 2026
- EPS
- −$0.07
EPS · −86% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $70M | +123% | Q1 2026 |
| Net Income | −$26M | −85% | Q1 2026 |
| EPS | −$0.07 | −86% | Q1 2026 |
| Gross Margin | 99% | n/a | Q1 2026 |
| Op Margin | −87% | n/a | Q1 2026 |
| Net Margin | −92% | n/a | Q1 2026 |
| ROE | −52% | n/a | Q1 2026 |
| ROA | −31% | n/a | Q1 2026 |
| ROIC | −93% | n/a | Q1 2026 |
| Free Cash Flow | −$180M | n/a | Q4 2024 · 5 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Lexicon Pharmaceuticals, Inc. (LXRX) - Revenue & ProfitRevenue & ProfitLexicon Pharmaceuticals, Inc. (LXRX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Biotechnology
The closest names by size in the same industry